Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial -

Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Infection and infectious diseases | Obstetrics and gynaecology | Paediatric and neonatal medicine
Summary
In low-risk women, clindamycin (1 or 3 courses) did not reduce late miscarriage or spontaneous very preterm delivery vs placebo (RR, 1.10; 95% CI 0.53–2.32; p=0.82). In high-risk women, both courses resulted in outcomes that were statistically similar (RR 0.67, 95% CI 0.23–2.00)
UKMi comment
A related commentary notes that these findings support NICE (CKS) recommendations that asymptomatic women without a history of previous early delivery should not be screened or treated for bacterial vaginosis.
Related links: Comment